Successful management of thrombotic thrombocytopenic purpura in a Jehovah's Witness without plasma exchange

2014 ◽  
Vol 30 (1) ◽  
pp. 46-49 ◽  
Author(s):  
Wanxing Chai ◽  
Abrar Chaudhry ◽  
Arthur P. Rabinowitz
2017 ◽  
Vol 1 (24) ◽  
pp. 2161-2165 ◽  
Author(s):  
James N. George ◽  
Steven A. Sandler ◽  
Joanna Stankiewicz

Key Points TTP in Jehovah’s Witness patients has been managed successfully without PEX. This experience, plus new TTP treatments, may make it possible for patients who are not Jehovah’s Witnesses to avoid PEX in the future.


2019 ◽  
Vol 7 (1) ◽  
pp. 8-11
Author(s):  
Ming Y Lim ◽  
Charles S Greenberg

The management of thrombotic thrombocytopenic purpura (TTP) presents a unique challenge in individuals who are unable to accept plasma due to religious beliefs, given that therapeutic plasma exchange (TPE) is the standard of care. A 61-year-old Jehovah’s Witness woman presented to our hospital with neurological symptoms and laboratory findings suggestive of TTP. On admission, she refused transfusion of blood products, specifically red blood cells, platelets, and plasma but accepted albumin and intravenous immunoglobulin (IVIG); fractions of plasma. She was started on steroids, IVIG, and TPE with albumin as replacement therapy with minimal improvement. After a detailed discussion with the patient and family, they agreed to accept cryosupernatant. The patient started TPE with cryosupernatant for replacement therapy, which resulted in clinical improvement. This case highlights the importance of an individualized approach with joint decision-making given the significant heterogeneity that exists in Jehovah’s Witnesses’ attitude toward the receipt of blood products.


2007 ◽  
Vol 82 (7) ◽  
pp. 679-681 ◽  
Author(s):  
Michael G. Martin ◽  
Nicole L. Whitlatch ◽  
Bijal Shah ◽  
Gowthami M. Arepally

1999 ◽  
Vol 102 (1) ◽  
pp. 12-16 ◽  
Author(s):  
Javier de la Rubia ◽  
Aurelio López ◽  
Francisco Arriaga ◽  
Ana Rosa Cid ◽  
Ana Isabel Vicente ◽  
...  

2020 ◽  
Vol 13 (3) ◽  
pp. 1368-1372
Author(s):  
Umit Yavuz Malkan ◽  
Murat Albayrak ◽  
Hacer Berna Ozturk ◽  
Merih Reis Aras ◽  
Bugra Saglam ◽  
...  

Microangiopathic hemolytic anemia (MAHA) can be observed as a paraneoplastic syndrome (PS) in certain tumors. MAHA-related signet ring cell carcinoma (SRCC) of an unknown origin is very infrequent. Herein we present a SRCC case presented with refractory acquired thrombotic thrombocytopenic purpura (TTP). A 35-year-old man applied to the emergency service with fatigue and headache. His laboratory tests resulted as white blood cell 9,020/µL, hemoglobin 3.5 g/dL, platelet 18,000/µL. Schistocytes, micro-spherocytes, and thrombocytopenia were observed in his blood smear. MAHA was present and he was considered as having TTP. Plasma exchange treatment was initiated; however, he was refractory to this treatment. Thorax and abdomen computerized tomography revealed thickening of minor curvature in stomach corpus with hepatogastric and paraceliac lymphadenopathy. Bone marrow (BM) investigation by our clinic resulted as the metastasis of adenocarcinoma. Ulceration and necrosis were observed by gastric endoscopy procedure. Biopsy was taken during endoscopic intervention, which resulted as SRCC. MAHA may be seen as a PS in some tumors, especially gastric cancers. Tumor-related MAHA is generally accompanied by BM metastases. As a result, BM investigation may be used as the main diagnostic method to find the underlying cancer. The clinical course of cases with tumor-related MAHA is usually poor, and these cases are usually refractory to plasma exchange treatment. In conclusion, physicians should suspect a malignancy and BM involvement when faced with a case of refractory TTP.


Sign in / Sign up

Export Citation Format

Share Document